```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:31:37 ON 13 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 13 Nov 2009  VOL 151 ISS 21
FILE LAST UPDATED: 12 Nov 2009  (20091112/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

During November, try the new LSUS format of legal status information
in the CA/CAplus family databases for free!  Complete details on the
number of free displays and other databases participating in this
offer appear in NEWS 10.

=>
=> d stat que l8
L1                STR
```




```
VAR G2=15/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  AT  10
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

```
RSPEC  14
NUMBER OF NODES IS  19

STEREO ATTRIBUTES: NONE
L3         2698 SEA FILE=REGISTRY SSS FUL L1
L5           66 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3
L6           16 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5 AND (AY=<2003 OR PY=<2003
                OR PRY=<2003 OR PD=< OCTOBER 30, 2003)
L7           12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5(L)(?DRUG? OR ?PHARMA? OR
                ?MEDIC? OR ?THERAP?)
L8            4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6 AND L7


=> d ibib abs hitstr l8 1-4

L8   ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2005:284200  HCAPLUS  Full-text
DOCUMENT NUMBER:          142:355286
TITLE:                    Preparation of heteroaryl-substituted
                          1,3-dihydroindol-2-one derivatives and medicaments
                          containing them
INVENTOR(S):              Lubisch, Wilfried; Hornberger, Wilfried; Oost,
                          Thorsten K.; Sauer, Daryl Richard; Unger, Liliane;
                          Wernet, Wolfgang
PATENT ASSIGNEE(S):       Abbott GmbH & Co. Kg, Germany
SOURCE:                   U.S. Pat. Appl. Publ., 24 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------------      ----   --------    --------------------     --------
     US 20050070718         A1    20050331    US 2003-675300           20030930 <--
     CA 2537598             A1    20050407    CA 2004-2537598          20040930 <--
     WO 2005030755          A1    20050407    WO 2004-EP10940          20040930 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1667993             A1    20060614    EP 2004-765719           20040930 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
     JP 2007507456          T     20070329    JP 2006-530059           20040930 <--
     MX 2006003558          A     20060831    MX 2006-3558             20060330 <--
     US 20070021607         A1    20070125    US 2006-440569           20060525 <--
     US 20070185126         A1    20070809    US 2007-574211           20070122 <--
PRIORITY APPLN. INFO.:                         US 2003-675300      A    20030930 <--
                                               WO 2004-EP10940     W    20040930
OTHER SOURCE(S):          CASREACT 142:355286; MARPAT 142:355286
```

GI



I II

AB The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivs. of the formula (I) [A = each (un)substituted aromatic heteromonocyclic or aromatic or partially aromatic heterobicyclic ring, where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups; R3, R4, R6, R7 = H, Cl, Br, iodo, F, cyano, CF3, OCF3, NO2, OH, C1-4 alkoxy, PhO, phenyl-C1-4 alkenyloxy, Ph, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, NH2, mono- or di(C1-4 alkyl)amino;or R3 and R4 are connected to give -CH:CH-CH:CH-, -(CH2)4- or -(CH2)3-; R5 = a radical (W)-(X)-(Y)-Z; where W = C1-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, O, O-(C1-4 alkylene), S, S-(C1-4 alkylene), N-(un)substituted NH or NH-(C1-4 alkylene), a bond; X = CO, CO-O, SO2, each (un)substituted NH, NH-CO, NH-SO2, or CO-NH, a bond; Y = C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, a bond; Z = H, E, each (un)substituted OH, NH2, or SH; where E = (un)substituted, unsatd., saturated or partially unsatd. mono, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms;] and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof. These compds. can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases, for example for the treatment of (1) depressions and/or bipolar disorders such as dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders, (2) anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, posttraumatic disorders, acute stress disorders and/or social phobia, (3) memory disorders and/or Alzheimer's disease, (4) psychoses and/or psychotic disorders, or (5) Cushing's syndrome. Thus, (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid dimethylamide hydrochloride (0.78 g, 4.0 mmol) was added to a solution of 3-(benzothiazol-2-yl)-3,5-dichloro-1,3-dihydroindol-2-one, in a mixture of dichloromethane 9, THF 2 and diisopropylethylamine 2 mL and the reaction mixture was stirred at room temperature for 48 h to give, after workup and silica gel chromatog., two diastereomers of (2S,4R)-1-[3-(Benzothiazol-2-yl)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-yl]- 4-hydroxypyrrolidine-2-carboxylic acid dimethylamide. NaH (12 mg 60% dispersion in mineral oil) was added to an ice-cold solution of the less polar diastereomer product from the above (115 mg, 0.25 mmol) in DMF (1.5 mL). The reaction mixture was stirred at 0° for 1 h and then treated with 2,4-dimethyloxyphenylsufonyl chloride (71 mg, 0.3 mmol), and stirred at room temperature for 1 h to give, after workup and silica gel chromatog., 93 mg (+)-

(2S,4R)-1-[3-(benzothiazol-2-yl)-5-chloro-1-[(2,4- dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4- hydroxypyrrolidine-2-carboxylic acid dimethylamide (II) as a white solid. II in vitro binding affinity to vasopressin VIb receptor with <50 nM.

IT 1053641-66-9 1053644-08-8 1056963-34-8
1056963-35-9 1056963-36-0 1056963-37-1
1056963-38-2 1056963-39-3 1056963-40-6
1056963-42-8 1056963-43-9 1056963-44-0
1056963-45-1 1056963-46-2 1056963-47-3
1056963-50-8 1056963-51-9 1056963-52-0
1056963-53-1 1056963-54-2 1056963-55-3
1056963-56-4 1056963-57-5 1056963-58-6
1056963-59-7 1056963-60-0 1056963-61-1
1056963-62-2 1056963-63-3 1056963-64-4
1056963-65-5 1056963-66-6 1056963-67-7
1056963-68-8 1056963-69-9 1056963-70-2
1056963-71-3
RL: PRPH (Prophetic)
(Preparation of heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them)

RN 1053641-66-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1053644-08-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(3-methylbenzo[b]thien-2-yl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 1056963-34-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(5-methyl-2-thienyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-35-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N,3-trimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-36-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-37-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(5-methoxy-2-pyridinyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-38-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(5-chloro-2-pyridinyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-39-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(5-methyl-2-pyridinyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1056963-40-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(6-methoxy-3-pyridinyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-42-8 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-pyridinyl)-, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl ester (CA INDEX NAME)



RN 1056963-43-9 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(4-pyridinyl)-, 5-chloro-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1056963-44-0 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-pyridinyl)-, 5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1056963-45-1 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(4-pyridinyl)-, 5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1056963-46-2 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-(4-pyridinyl)-, 5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1056963-47-3 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(1-methyl-4-piperidinyl)-, 5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl ester (CA INDEX NAME)



RN 1056963-50-8 HCAPLUS
CN 4-Piperidinecarboxamide, N-[5-chloro-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl]-1-(4-pyridinyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1056963-51-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-52-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(2-benzothiazolyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-53-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 1056963-54-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methyl-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 1056963-55-3 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chloro-3-pyridinyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 1056963-56-4 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(4-methyl-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-57-5 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-(2-pyrazinyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-,

(2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-58-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(3,6-dimethoxy-4-pyridazinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 1056963-59-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-

2,3-dihydro-3-(4-isoquinolinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-60-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-(3-quinolinyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-61-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-(2-thiazolyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-62-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(1-methyl-1H-benzimidazol-2-yl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-63-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(1-methyl-1H-imidazol-2-yl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-64-4 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[3-(2-benzoxazolyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-65-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methylbenzo[b]thien-2-yl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-66-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methyl-2-thienyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-67-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-benzo[b]thien-7-yl-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 1056963-68-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(7-benzofuranyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 1056963-69-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(2-benzofuranyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-70-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methyl-2-furanyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1056963-71-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(3-furanyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 848865-36-1P 848865-38-3P 848865-40-7P
848865-42-9P 848865-44-1P 848865-46-3P
848865-48-5P 848865-50-9P 848865-52-1P
848865-54-3P 848865-56-5P 848865-57-6P
848865-58-7P 848865-59-8P 848865-60-1P
848865-61-2P 848865-62-3P 848865-63-4P
848865-64-5P 848865-65-6P 848865-66-7P
848865-67-8P 848865-68-9P 848865-69-0P
848865-70-3P 848865-71-4P 848865-72-5P
848865-73-6P 848865-74-7P 848865-75-8P
848865-76-9P 848865-77-0P 848865-78-1P
848865-79-2P 848865-80-5P 848865-81-6P
848865-82-7P 848865-87-2P,
5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxypyrimidin-5-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(pyridin-2-yl)piperazine-1-carboxylate
848865-88-3P, 5-Chloro-3-(2,4-dimethoxypyrimidin-5-yl)-2-oxo-1-[(quinolin-8-yl)sulfonyl]-2,3-dihydro-1H-indol-3-yl 4-(pyridin-2-yl)piperazine-1-carboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl(phenylsulfonyl)dihydroindolone derivs. for control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases)

RN 848865-36-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-3-(2-benzothiazolyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-38-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-3-(2-benzothiazolyl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-40-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-42-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-44-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 848865-46-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 848865-48-5 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methoxy-2-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 848865-50-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(4-methoxy-3-pyridinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-52-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methoxy-2-pyrazinyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-

dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 848865-54-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-56-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-(2-thienylsulfonyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-57-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-(3-thienylsulfonyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-58-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(5-chloro-2-thienyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-59-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(3-bromo-5-chloro-2-thienyl)sulfonyl]-5-

chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-60-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(4-bromo-5-chloro-2-thienyl)sulfonyl]-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-61-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(4,5-dichloro-2-thienyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-62-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-(benzo[b]thien-2-ylsulfonyl)-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 848865-63-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-64-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-65-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-66-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-67-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-68-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-69-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethyl-5-thiazolyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-70-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-71-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-(2-pyridinylsulfonyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-72-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(5-bromo-2-pyridinyl)sulfonyl]-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-73-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(5-bromo-3-methyl-2-pyridinyl)sulfonyl]-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-74-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(3,5-dimethyl-2-pyridinyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-75-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-(3-pyridinylsulfonyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-76-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[[6-(4-morpholinyl)-3-pyridinyl]sulfonyl]-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 848865-77-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-[(6-phenoxy-3-pyridinyl)sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-78-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-5-

chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-79-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-80-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-[(1,2,3,4-tetrahydro-7-isoquinolinyl)sulfonyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 848865-81-6 HCAPLUS
CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-hydroxy-3-(3-methyl-2-thienyl)- (CA INDEX NAME)



RN 848865-82-7 HCAPLUS
CN Carbamic acid, (4-chlorophenyl)-, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methyl-2-thienyl)-2-oxo-1H-indol-3-yl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 848865-87-2 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-pyridinyl)-, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1H-indol-3-yl ester (CA INDEX NAME)



RN 848865-88-3 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-pyridinyl)-, 5-chloro-3-(2,4-dimethoxy-5-pyrimidinyl)-2,3-dihydro-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 944798-17-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heteroaryl(phenylsulfonyl)dihydroindolone derivs. for control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases)
RN 944798-17-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1-(8-quinolinylsulfonyl)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L8 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:714579 HCAPLUS Full-text
DOCUMENT NUMBER: 140:245674
TITLE: Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals
AUTHOR(S): Serradeil-Le Gal, Claudine; Sylvain, Derick; Gabrielle, Brossard; Maurice, Manning; Jacques, Simiand; Rolf, Gaillard; Guy, Griebel; Gilles, Guillon
CORPORATE SOURCE: Sanofi-Synthelabo Recherche, Toulouse, Fr.
SOURCE: Stress (Abingdon, United Kingdom) (2003), 6(3), 199-206
CODEN: STREFR; ISSN: 1025-3890
PUBLISHER: Taylor & Francis Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. By activating three distinct vasopressin receptor isoforms called V1a-R, V1b-R (V3-R) and V2-R, vasopressin (VP) mediates a wide number of biol. effects in mammals and may be involved in several pathol. states. Up to now only specific V1a and V2 receptor agonists and antagonists have been successfully designed. The role of the V1b-R still remains partially unknown, due to the lack of selective V1b-R ligands and orally-active mols., which are crucial tools for investigating the central and peripheral functions or pathol. disorders associated with this receptor. In this review, we report the biol. and pharmacol. properties of the first two specific V1b-R ligands: d[Cha4] AVP, a high affinity V1b-R agonist and SSR 149415, a potent orally-active V1b-R antagonist with good selectivity with respect to other VP/OT receptor isoforms and able to control ACTH secretion in vitro and in vivo. Indeed, these mols. constitute invaluable tools for exploring the central and peripheral roles of VP mediated via V1b receptors. Interestingly, SSR 149415 displays potent anxiolytic and antidepressant-like activities, indicating that this new class of drugs has a promising therapeutical potential in the treatment of stress-related disorders, anxiety and depression.

IT 439687-69-1, SSR 149415
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasopressin V1b receptor agonist and antagonist functional and pharmacol. characterization in mammals)

RN 439687-69-1 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:935598 HCAPLUS Full-text

DOCUMENT NUMBER: 136:69734

TITLE: Preparation and use of dihydroindolone derivatives as vasopressin receptor ligands

INVENTOR(S): Roux, Richard; Serradeil-Le Gal, Claudine; Wagnon, Jean

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098295	A1	20011227	WO 2001-FR1919	20010619 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2810320	A1	20011221	FR 2000-7885	20000619 <--
FR 2810320	B1	20020823		
TW 287011	B	20070921	TW 2001-90114443	20010614 <--
EP 1296976	A1	20030402	EP 2001-947534	20010619 <--
EP 1296976	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003118	A2	20040128	HU 2003-3118	20010619 <--
HU 2003003118	A3	20070828		
JP 2004502654	T	20040129	JP 2002-504251	20010619 <--
AT 287881	T	20050215	AT 2001-947534	20010619 <--
ES 2236260	T3	20050716	ES 2001-947534	20010619 <--
US 20030162767	A1	20030828	US 2002-311435	20021216 <--
US 6864277	B2	20050308		
US 20050176770	A1	20050811	US 2005-64896	20050224 <--
US 7425566	B2	20080916		

PRIORITY APPLN. INFO.:
FR 2000-7885 A 20000619 <--
WO 2001-FR1919 W 20010619 <--
US 2002-311435 A3 20021216 <--

OTHER SOURCE(S): MARPAT 136:69734
GI



I



II

AB Title compds. I [W = O, S; R1 = halo, alkyl, alkoxy, CF3(O); R2 = H, halo, alkyl, alkoxy, CF3 or R2 is in the 6-position of the indol-2-one nucleus and forms a trimethylene bridge with R1; R3 halo, OH, alkyl, alkoxy, CF3O; R4 = H, halo, alkyl, alkoxy, or R3, R4 form a methylenedioxy bridge in the 2,3 position of the Ph ring; R5 = EtNH, NMe2, azetidin-1-yl, alkoxy; R6 = alkoxy; R7 = alkoxy] were prepared Over 35 synthetic examples were disclosed. E.g., addition 2-Methoxyphenylmagnesium bromide to 5-chloro-1H-indol-2,3-dione in ether followed by treatment of the resulting carbinol with thionyl chloride provided the corresponding α-chloro-indol-2-one derivative This was reacted with 2(S)-N,N-dimethylcarboxamidopyrrolidine (CHCl3, THF, i-Pr2NEt) and the resulting indole sulfonylated with 2,4-dimethoxysulfonyl chloride (DMF, NaH) which yielded II. I exhibit affinity and selectivity for V1b arginine-vasopressin receptors or for both V1b and V1a arginine-vasopressin receptors.

IT 383425-49-8P 383425-50-1P 383425-53-4P
383425-54-5P 383425-55-6P 383425-56-7P
383425-58-9P 383425-59-0P 383425-60-3P
383425-61-4P, 1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-N,N-dimethylpiperidine-2-carboxamide 383425-62-5P 383425-63-6P,
1-[3-(2-Chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-5,6-dimethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N,N-dimethylpiperidine-2-carboxamide
383425-64-7P 383425-65-8P 383425-66-9P
383425-67-0P 383425-68-1P 383425-69-2P
383425-70-5P 383425-71-6P 383425-72-7P
383425-73-8P 383425-74-9P 383425-75-0P
383425-76-1P 383425-77-2P 383425-78-3P
383425-79-4P 383426-02-6P 383426-03-7P
383426-04-8P 383426-05-9P 383426-06-0P
383426-07-1P 383426-08-2P 383426-09-3P
383426-10-6P 383426-11-7P 383426-12-8P
383426-13-9P 383426-14-0P 383427-23-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of dihydroindolone derivs. as vasopressin receptor ligands)

RN 383425-49-8 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-50-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N-ethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-53-4 HCAPLUS
CN 2H-Indol-2-one, 3-[(2S)-2-(1-azetidinylcarbonyl)-1-pyrrolidinyl]-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-54-5 HCAPLUS
CN 2-Pyrrolidinecarbothioamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 383425-55-6 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-56-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-hydroxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 383425-58-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-5-(trifluoromethoxy)-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-59-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-60-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[6-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-61-4 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5-chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 383425-62-5 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[(3R)-5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-63-6 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5,6-dimethyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 383425-64-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-65-8 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-66-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-67-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,4-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-68-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,6-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-69-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(1,3-benzodioxol-4-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 383425-70-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-71-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-6-methylphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-72-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-73-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[4,5-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 383425-74-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-75-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-6-methoxy-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-76-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-6-methylphenyl)-5,6-dimethyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-77-2 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 383425-78-3 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-79-4 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-02-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-03-7 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[(3S)-5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-04-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(3-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 383426-05-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(4-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 383426-06-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-07-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(3,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-08-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[2-(trifluoromethoxy)phenyl]-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-09-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-4-methoxy-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 383426-10-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-7-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-11-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[4-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 383426-12-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-1,2,3,5,6,7-hexahydro-3-(2-methoxyphenyl)-2-oxocyclopent[f]indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-13-9 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383426-14-0 HCAPLUS
CN 2-Piperidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-7-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383427-23-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 383425-51-2P 383425-52-3P 383425-57-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and use of dihydroindolone derivs. as vasopressin receptor ligands)
RN 383425-51-2 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-52-3 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 383425-57-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[2-(phenylmethoxy)phenyl]-1H-indol-3-yl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:565027 HCAPLUS Full-text
DOCUMENT NUMBER: 135:137403
TITLE: Preparation of 1,3-dihydro-2H-indol-2-ones with selective binding affinity for the V1b arginine-vasopressin receptor for pharmaceutical use
INVENTOR(S): Schoentjes, Bruno; Serradeil-Le Gal, Claudine; Wagnon, Jean
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055134	A2	20010802	WO 2001-FR228	20010124 <--
WO 2001055134	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2804115	A1	20010727	FR 2000-958	20000125 <--
FR 2804115	B1	20020308		
AU 2001035596	A	20010807	AU 2001-35596	20010124 <--
EP 1254134	A2	20021106	EP 2001-907687	20010124 <--
EP 1254134	B1	20030723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

HU 2002004157	A2	20030428	HU 2002-4157		20010124 <--
HU 2002004157	A3	20050428			
HU 225157	B1	20060728			
JP 2003523354	T	20030805	JP 2001-560993		20010124 <--
AT 245644	T	20030815	AT 2001-907687		20010124 <--
ES 2203596	T3	20040416	ES 2001-907687		20010124 <--
US 20030139413	A1	20030724	US 2002-182638		20021125 <--
US 6624164	B2	20030923			
PRIORITY APPLN. INFO.:			FR 2000-958	A	20000125 <--
			WO 2001-FR228	W	20010124 <--

OTHER SOURCE(S): MARPAT 135:137403

GI



I



II

AB Morpholinylindolines, such as I [R1 = CF3, OCF3, halogen, alkyl, alkoxy; R2 = H, CF3, halogen, alkyl, alkoxy; R3 = OH, OCF3, halogen, alkyl, alkoxy; R4 = H, halogen, alkyl, alkoxy; R3R4 = OCH2O; R5 = NHEt, NMe2, azetidin-1-yl, alkoxy; R6, R7 = alkoxy] having affinity and selectivity for V1b receptors or for both V1b and V1a arginine-vasopressin receptors, were prepared for pharmaceutical use in the treatment of a variety of conditions, such as hypertension, migraine, myocardial infarction, pulmonary hypertension, etc. Thus, both diastereomers of morpholinylindolinone II were prepared via a multistep synthetic sequence starting from 1-bromo-2-methoxybenzene, 5-chloro-1H-indole-2,3-dione, L-serine, and 2,4-dimethoxybenzenesulfonyl chloride. Binding affinity of the prepared morpholinylindolines for V1b and V1a arginine-vasopressin receptors was tested with the V1b receptor being selectively inhibited.

IT 352030-09-2P 352030-10-5P 352030-11-6P
352030-12-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,3-dihydro-2H-indol-2-ones with selective binding affinity for the V1b arginine-vasopressin receptor for pharmaceutical use treating conditions such as hypertension)

RN 352030-09-2 HCAPLUS

CN 3-Morpholinecarboxamide, 4-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352030-10-5 HCAPLUS
CN 3-Morpholinecarboxamide, 4-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352030-11-6 HCAPLUS
CN 3-Morpholinecarboxamide, 4-[6-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352030-12-7 HCAPLUS
CN 3-Morpholinecarboxamide, 4-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que l9
L1 STR

VAR G2=15/HY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 10
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 14
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L3 2698 SEA FILE=REGISTRY SSS FUL L1
L5 66 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L6 16 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 AND (AY=<2003 OR PY=<2003 OR PRY=<2003 OR PD=< OCTOBER 30, 2003)
L7 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L5(L)(?DRUG? OR ?PHARMA? OR ?MEDIC? OR ?THERAP?)
L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 AND L7

L9 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 NOT L8

=> d ibib abs hitstr l9 1-12

L9 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:672891 HCAPLUS Full-text
DOCUMENT NUMBER: 143:146733
TITLE: Methods using V1b receptor modulators for treating vasomotor symptoms
INVENTOR(S): Leventhal, Liza; Ring, Robert H.
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050165082	A1	20050728	US 2004-13019	20041215 <--
PRIORITY APPLN. INFO.:			US 2003-529930P P	20031216 <--

AB The invention discloses methods for treating at least one vasomotor symptom, e.g. hot flush, caused by, inter alia, thermoregulatory dysfunction, in a subject in need thereof by administering to the subject a compound or composition of compds. that modulate the V1b receptor.

IT 352276-92-7 352276-92-7D, isomers
352276-93-8 352276-93-8D, isomers
352276-95-0 352276-95-0D, isomers
352276-97-2 352276-97-2D, isomers
352276-99-4 352276-99-4D, isomers
352277-01-1 352277-01-1D, isomers
352277-07-7 352277-07-7D, isomers
352277-09-9 352277-09-9D, isomers
352277-11-3 352277-11-3D, isomers
352277-13-5 352277-13-5D, isomers
352277-15-7 352277-15-7D, isomers
352277-17-9 352277-17-9D, isomers
352277-19-1 352277-19-1D, isomers
352277-21-5 352277-21-5D, isomers
352277-23-7 352277-23-7D, isomers
352277-25-9 352277-25-9D, isomers
352277-27-1 352277-27-1D, isomers
352277-33-9 352277-33-9D, isomers
352277-37-3 352277-37-3D, isomers
352277-39-5 352277-39-5D, isomers
352277-41-9 352277-41-9D, isomers
352277-43-1 352277-43-1D, isomers
352277-45-3 352277-45-3D, isomers
352277-47-5 352277-47-5D, isomers
352277-50-0 352277-50-0D, isomers
352277-52-2 352277-52-2D, isomers
352277-55-5 352277-55-5D, isomers
352277-61-3 352277-61-3D, isomers
859987-33-0 859987-33-0D, isomers
859987-34-1 859987-34-1D, isomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(V1b receptor modulators for treating vasomotor symptoms)

RN 352276-92-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-92-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-93-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-93-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-95-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-95-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-97-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-97-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-99-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-99-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-01-1 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-01-1 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-07-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-07-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-09-9 HCAPLUS
CN 2H-Indol-2-one, 3-[(2S,4R)-2-(1-azetidinylcarbonyl)-4-hydroxy-1-pyrrolidinyl]-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-09-9 HCAPLUS
CN 2H-Indol-2-one, 3-[(2S,4R)-2-(1-azetidinylcarbonyl)-4-hydroxy-1-pyrrolidinyl]-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-11-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-5-(trifluoromethoxy)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-11-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-5-(trifluoromethoxy)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-13-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-13-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-15-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5,6-dimethyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-15-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5,6-dimethyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-17-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-17-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-19-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-19-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-21-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[6-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-21-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[6-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-23-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-ethoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-23-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-ethoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-25-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-25-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-27-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-27-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-33-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-33-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-37-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-difluorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-37-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-difluorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-39-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,4-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-39-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,4-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-41-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(1,3-benzodioxol-4-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-41-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(1,3-benzodioxol-4-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-43-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-43-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-

yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-45-3 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-45-3 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-47-5 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-47-5 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-50-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-2-oxoethoxy]-N,N-dimethyl-, (2S,4R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 352277-50-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-2-oxoethoxy]-N,N-dimethyl-, (2S,4R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 352277-52-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-oxo-2-(1-piperazinyl)ethoxy]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-52-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-oxo-2-(1-piperazinyl)ethoxy]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-55-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-(4-morpholinyl)-2-oxoethoxy]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-55-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-(4-morpholinyl)-2-oxoethoxy]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-61-3 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-methoxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-61-3 HCAPLUS

CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-methoxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859987-33-0 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-methoxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859987-33-0 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-methoxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859987-34-1 HCAPLUS
CN 4-Morpholinepropanoic acid, (3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 859987-34-1 HCAPLUS
CN 4-Morpholinepropanoic acid, (3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 439687-69-1, SSR149415
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(V1b receptor modulators for treating vasomotor symptoms)
RN 439687-69-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L9 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:219790 HCAPLUS Full-text
DOCUMENT NUMBER: 142:298331
TITLE: Preparation of 1-[1-(benzenesulfonyl)-3-phenyl-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-fluoro-L-proline derivatives as antagonists of arginine-vasopressin V1b receptor
INVENTOR(S): Kumagai, Toshihito; Kuwada, Takeshi; Shibata, Tsuyoshi; Hayashi, Masato; Fujisawa, Yuri; Sekiguchi, Yoshinori
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021534	A1	20050310	WO 2004-JP12398	20040827 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1659121	A1	20060524	EP 2004-772354	20040827 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20060276449	A1	20061207	US 2006-569833	20060228 <--
US 7528124	B2	20090505		
PRIORITY APPLN. INFO.:			JP 2003-209401	A 20030828 <--
			WO 2004-JP12398	W 20040827
OTHER SOURCE(S):	MARPAT 142:298331			

GI



I

AB 1,3-Dihydro-2H-indol-2-one derivs. represented by the formula (I) (wherein R1 = halogeno, C1-4 alkyl, C1-4 alkoxy, CF3, CF3O; R2 = H, halogeno, C1-4 alkyl, C1-4 alkoxy, CF3; or R2 is present in the 6-position of the indol-2-one and is bonded to R1 to form C3-6 alkylene; R3 = halogeno, hydroxy, C1-4 alkyl, C1-4 alkoxy, CF3O; R4 = H, halogeno, C1-4 alkyl, C1-4 alkoxy; or R4 is present in the 3-position of the Ph and is bonded to R3 to form methylenedioxy; R5 = H, F; R6 = ethylamino, dimethylamino, azetidin-1-yl, C1-4 alkoxy; R7, R8 = C1-4 alkoxy) or pharmaceutically acceptable salts thereof are prepared These compds. have antagonistic activity against an arginine-vasopressin V1b receptor and are useful for the prevention or treatment of depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington chorea, eating disorder, hypertension, digestive tract diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immune diseases, and alopecia. Thus, 3.78 g 3,5-dichloro-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one and 7.27 g (4R)-4-fluoro-N,N-dimethyl-L-prolinamide trifluoroacetate were suspended in 40 mL CHCl3, treated with 7.47 g Et3N, and stirred at room temperature for 13 h to give, after silica gel chromatog., (+)- and (-)-(4R)-1-[5-chloro-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-L-prolinamide (II). (-)-II (2.00 g) was added to a mixture of 0.215 g NaH and 20 mL DMF under ice-cooling, stirred for 40 min, treated with a solution of 1.27 g 2,4-dimethoxybenzenesulfonyl chloride in 5 mL DMF, and stirred for 35 min under ice-cooling and then at room temperature for 1 h to give (-)-(4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3- (2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-L- prolinamide (III). III inhibited the binding of [3H]Arg-vasopressin to arginine-vasopressin receptor V1b and V1a by 50% at 1-100 x 10-9 M and 10-8-10-6 M, resp.

IT 847865-89-8P 847865-90-1P 847865-91-2P
847865-92-3P 847865-93-4P 847865-94-5P
847865-96-7P 847865-97-8P 847865-98-9P
847865-99-0P 847866-01-7P 847866-02-8P
847866-03-9P 847866-04-0P 847866-05-1P
847866-07-3P 847866-08-4P 847866-09-5P
847866-10-8P 847866-12-0P 847866-14-2P
847866-15-3P 847866-16-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-[1-(benzenesulfonyl)-3-phenyl-2-oxo-1,3-dihydro-2H-indol-3-

yl]-4-fluoro-L-proline derivs. as antagonists of arginine-vasopressin V1b receptor)

RN 847865-89-8 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-90-1 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-91-2 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4,4-difluoro-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-92-3 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-, methyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-93-4 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 847865-94-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-96-7 HCAPLUS
CN 2H-Indol-2-one, 3-[(2S)-2-(1-azetidinylcarbonyl)-4-fluoro-1-pyrrolidinyl]-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-97-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N-ethyl-4-fluoro-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-98-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-3-(2,4-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5,6-dimethoxy-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847865-99-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethyl)phenyl]-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-01-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-1,2,3,5,6,7-hexahydro-3-(2-hydroxyphenyl)-2-oxocyclopent[f]indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-02-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-2,3-dihydro-2-oxo-5-(trifluoromethyl)-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-03-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[2-(trifluoromethoxy)phenyl]-6-(trifluoromethyl)-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-04-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-5-(trifluoromethoxy)-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-05-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-07-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-4,5-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-5-methylphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-08-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(5-chloro-2-methoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-4-methyl-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-09-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-3-(1,3-benzodioxol-4-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-10-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dibutoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-12-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-3-(2,4-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5,6-dimethoxy-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-14-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-15-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-4,5-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxy-5-methylphenyl)-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847866-16-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-3-(1,3-benzodioxol-4-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 847866-69-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-[1-(benzenesulfonyl)-3-phenyl-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-fluoro-L-proline derivs. as antagonists of arginine-vasopressin V1b receptor)
RN 847866-69-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-1,2,3,5,6,7-hexahydro-2-oxo-3-[2-(phenylmethoxy)phenyl]cyclopent[f]indol-3-yl]-4-fluoro-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:177819 HCAPLUS Full-text
DOCUMENT NUMBER: 142:280224
TITLE: A combinatorial preparation of N-containing heterocycles, useful as caspase-3 inhibitors
INVENTOR(S): Ivashchenko, Alexander Vasilievich; Ilyin, Alexey Petrovich; Kobak, Vladimir Vasilievich; Kravchenko, Dmitri Vladimirovich; Khvat, Alexander Viktorovich; Tkachenko, Sergey Yevgenievich; Okun, Ilya Matusovich
PATENT ASSIGNEE(S): Chemical Diversity Research Institute, Ltd., Russia
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005018531	A2	20050303	WO 2004-RU331	20040825 <--
WO 2005018531	A3	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
RU 2248978	C1	20050327	RU 2003-125936	20030826 <--
RU 2259999	C2	20050910	RU 2003-125938	20030826 <--
RU 2251546	C1	20050510	RU 2003-126299	20030829 <--
PRIORITY APPLN. INFO.:			RU 2003-125936 A	20030826 <--
			RU 2003-125938 A	20030826 <--
			RU 2003-126299 A	20030829 <--

OTHER SOURCE(S): MARPAT 142:280224
GI



I



II



III



IV

AB The invention relates to a combinatorial preparation of N-containing heterocycles of formulas I, II, and III [wherein: R1, R2, and R3 are independently H or inert substituents; R4 is (cyclo)alkyl, aryl, or heterocyclyl; R5 is O or 4-7-membered (hetero)cycle attached to the pyrrole ring by carbon; W is (un)substituted carbocycle or heterocycle; X is O or S], useful as caspase-3 inhibitors. For instance, 2,3-dihydro-1H-benzo[g]pteridin-4-one derivs. were prepared with yields of 40-90%. The invention compds. were tested for caspase-3 inhibition (IV, IC50 = 265 nM).

IT 361166-05-4P 361166-07-6P 430428-93-6P
847363-16-0P 847363-18-2P 847363-23-9P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of N-containing heterocycles useful as caspase 3 inhibitors)

RN 361166-05-4 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-1-[(4-methylphenyl)sulfonyl]-3-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]- (CA INDEX NAME)



RN 361166-07-6 HCAPLUS

CN 2H-Indol-2-one, 3-[3-(2-furanylmethyl)-4-oxo-2-thioxo-5-thiazolidinylidene]-1,3-dihydro-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 430428-93-6 HCAPLUS
CN 2H-Indol-2-one, 3-[3-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-4-oxo-2-thioxo-5-thiazolidinylidene]-1,3-dihydro-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 847363-16-0 HCAPLUS
CN 2H-Indol-2-one, 3-[3-(1,3-benzodioxol-5-yl)-4-oxo-2-thioxo-5-thiazolidinylidene]-1,3-dihydro-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 847363-18-2 HCAPLUS
CN 3-Thiazolidineacetic acid, 5-[1,2-dihydro-1-[(4-methylphenyl)sulfonyl]-2-oxo-3H-indol-3-ylidene]-4-oxo-2-thioxo- (CA INDEX NAME)



RN 847363-23-9 HCAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-[1,2-dihydro-1-[(4-methylphenyl)sulfonyl]-2-oxo-3H-indol-3-ylidene]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-, 3-ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:59993 HCAPLUS Full-text
DOCUMENT NUMBER: 140:128266
TITLE: Preparation of acyloxypyrrolidines as vasopressin receptors V1a and V1b ligands
INVENTOR(S): Aulombard, Alain; Garcia, Georges; Serradeil Le Gal, Claudine; Wagnon, Jean
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: Fr. Demande, 22 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

FR 2842527	A1	20040123	FR 2002-9242	20020719 <--
FR 2842527	B1	20050128		
CA 2492224	A1	20040129	CA 2003-2492224	20030717 <--
WO 2004009585	A2	20040129	WO 2003-FR2262	20030717 <--
WO 2004009585	A3	20040506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003271815	A1	20040209	AU 2003-271815	20030717 <--
AU 2003271815	B2	20090312		
BR 2003012800	A	20050419	BR 2003-12800	20030717 <--
EP 1525198	A2	20050427	EP 2003-753652	20030717 <--
EP 1525198	B1	20051207		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1681806	A	20051012	CN 2003-821817	20030717 <--
JP 2005537271	T	20051208	JP 2004-522252	20030717 <--
JP 4264414	B2	20090520		
AT 312092	T	20051215	AT 2003-753652	20030717 <--
ES 2254962	T3	20060616	ES 2003-753652	20030717 <--
NZ 537615	A	20061130	NZ 2003-537615	20030717 <--
TW 274751	B	20070301	TW 2003-92119736	20030718 <--
ZA 2005000478	A	20060726	ZA 2005-478	20050118 <--
NO 2005000292	A	20050419	NO 2005-292	20050119 <--
MX 2005000822	A	20050829	MX 2005-822	20050119 <--
US 20050192335	A1	20050901	US 2005-38384	20050119 <--
US 7202267	B2	20070410		
IN 2005KN00137	A	20050805	IN 2005-KN137	20050204 <--
HK 1074444	A1	20060714	HK 2005-108399	20050923 <--

PRIORITY APPLN. INFO.:			FR 2002-9242 A	20020719 <--
			WO 2003-FR2262 W	20030717 <--

OTHER SOURCE(S): MARPAT 140:128266
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = H, cyclo/alkyl, CH2CH2CO2H; and their salts with organic or inorg. bases, solvates and/or hydrates] were prepared as selective ligands for binding to vasopressin receptors V1a and V1b or for V1b receptor alone for treating arginine-vasopressin related disorders. Thus, treating the alc. II with acetic anhydride in DMAP at reflux for 30 min gave I (R1 = Me) (m.p. = 194-195°). In an in vitro test, III showed an IC50 values of 3.4 nM, and 84 nM for the binding to human vasopressin receptor V1b, and V1a resp.

IT 439687-69-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of acyloxypyrrolidines as vasopressin receptors V1a and V1b ligands)

RN 439687-69-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 649726-53-4P, (3R,5S)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl acetate
649726-58-9P, (3R,5S)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl propionate
649726-60-3P, (3R,5S)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl formate
649726-62-5P, (3R,5S)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl cyclohexanecarboxylate
649726-64-7P, (3R,5S)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl 2-methylpropanoate
649726-66-9P, 4-[[(3R,5S)-1-[(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2,3-dihydro-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]-4-oxobutanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vasopressin receptors V1a and V1b ligand; preparation of acyloxypyrrolidines as vasopressin receptors V1a and V1b ligands)
RN 649726-53-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 4-(acetyloxy)-1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 649726-58-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-(1-oxopropoxy)-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 649726-60-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-(formyloxy)-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 649726-62-5 HCAPLUS
CN Cyclohexanecarboxylic acid, (3R,5S)-1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 649726-64-7 HCAPLUS
CN Propanoic acid, 2-methyl-, (3R,5S)-1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 649726-66-9 HCAPLUS
CN Butanedioic acid, 1-[(3R,5S)-1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl] ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:591307 HCAPLUS Full-text
DOCUMENT NUMBER: 139:143997
TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): Ceretek LLC, USA
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121 <--
WO 2003062392	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2473740	A1	20030731	CA 2003-2473740	20030121 <--
AU 2003214873	A1	20030902	AU 2003-214873	20030121 <--
EP 1513522	A2	20050316	EP 2003-710713	20030121 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005519915	T	20050707	JP 2003-562260	20030121 <--
US 20050261298	A1	20051124	US 2003-390428	20030314 <--

PRIORITY APPLN. INFO.:

US 2002-350445P	P	20020118 <--
US 2002-350446P	P	20020118 <--
US 2002-350447P	P	20020118 <--
US 2002-350448P	P	20020118 <--
WO 2003-US1881	W	20030121 <--
US 2003-352579	B2	20030127 <--

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT 342384-25-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Edg receptor modulators for treatment of Edg receptor-associated conditions)

RN 342384-25-2 HCAPLUS

CN 2H-Indol-2-one, 3-(2-amino-4-oxo-5(4H)-thiazolylidene)-1,3-dihydro-1-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:371451 HCAPLUS Full-text
DOCUMENT NUMBER: 137:288889
TITLE: Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
AUTHOR(S): Griebel, Guy; Simiand, Jacques; Serradeil-Le Gal, Claudine; Wagnon, Jean; Pascal, Marc; Scatton, Bernard; Maffrand, Jean-Pierre; Soubrie, Philippe
CORPORATE SOURCE: Sanofi-Synthelabo Recherche, Bagneux, 92220, Fr.
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(9), 6370-6375
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The limbic localization of the arginine vasopressin V1b receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V1b receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social defeat-induced anxiety) rodent models of anxiety, and in two models of depression [forced swimming and chronic mild stress (CMS)]. When tested in classical tests of anxiety, SSR149415 produced anxiolytic-like activity at doses that ranged from 1 to 30 mg/kg (i.p. or p.o.), but the magnitude of these effects was overall less than that of the benzodiazepine anxiolytic diazepam, which was used as a pos. control. In contrast, SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.). In the forced swimming test, SSR149415 (10–30 mg/kg, p.o.) produced antidepressant-like effects in both normal and hypophysectomized rats. Moreover, in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the phys. state, anxiety, despair, and the loss of coping behavior produced by stress. These findings point to a role for vasopressin in the modulation of emotional processes via the V1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.

IT 439687-69-1, SSR 149415
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anxiolytic- and antidepressant-like effects of non-peptide vasopressin

V1b receptor antagonist, SSR149415)
RN 439687-69-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 152 THERE ARE 152 CAPLUS RECORDS THAT CITE THIS RECORD (152 CITINGS)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:203647 HCAPLUS Full-text
DOCUMENT NUMBER: 137:57427
TITLE: Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
AUTHOR(S): Serradeil-Le Gal, Claudine; Wagnon, Jean; Simiand, Jacques; Griebel, Guy; Lacour, Colette; Guillon, Gilles; Barberis, Claude; Brossard, Gabrielle; Soubrie, Philippe; Nisato, Dino; Pascal, Marc; Pruss, Rebecca; Scatton, Bernard; Maffrand, Jean-Pierre; Le Fur, Gerard
CORPORATE SOURCE: Exploratory Research Department, Sanofi-Synthelabo Recherche, Bagneux, Fr.
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2002), 300(3), 1122-1130
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)- 2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide(SSR149415), the first selective, nonpeptide vasopressin V1b receptor antagonist yet described, has been characterized in vitro and in vivo.

SSR149415 showed competitive nanomolar affinity for animal and human V1b receptors and exhibited much lower affinity for rat and human V1a, V2, and oxytocin receptors. Moreover, this compound did not interact with a large number of other receptors, enzymes, or ion channels. In vitro, SSR149415 behaved as a full antagonist and potently inhibited arginine vasopressin (AVP)-induced Ca2+ increase in Chinese hamster ovary cells expressing rat or human V1b receptors. The in vivo activity of SSR149415 has been studied in several models of elevated corticotropin secretion in conscious rats. SSR149415 inhibited exogenous AVP-induced increase in plasma corticotropin, from 3 mg/kg i.p. and 10 mg/kg p.o. upwards. Similarly, this compound antagonized AVP-potentiated corticotropin release provoked by exogenous corticoliberin at 3 mg/kg p.o. The effect lasted for more than 4 h at 10 mg/kg p.o. showing a long-lasting oral effect. SSR149415 (10 mg/kg p.o.) also blocked corticotropin secretion induced by endogenous AVP increase subsequent to body water loss. Moreover, 10 mg/kg i.p SSR149415 inhibited plasma corticotropin elevation after restraint-stress in rats by 50%. In the four-plate test, a mouse model of anxiety, SSR149415 (3 mg/kg p.o. upwards) displayed anxiolytic-like activity after acute and 7-day repeated administrations. Thus, SSR149415 is a potent, selective, and orally active V1b receptor antagonist. It represents a unique tool for exploring the functional role of V1b receptors and deserves to be clin. investigated in the field of stress and anxiety.

IT 439687-69-1, SSR 149415
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization of SSR149415 on activity of vasopressin V1b receptor)

RN 439687-69-1 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 78 THERE ARE 78 CAPLUS RECORDS THAT CITE THIS RECORD (78 CITINGS)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:565024 HCAPLUS Full-text

DOCUMENT NUMBER: 135:152717

TITLE: Preparation of N-oxoindolylpyrrolidine-2-carboxamides and analogs as vasopressin V1a and V1b receptor

ligands
INVENTOR(S): Roux, Richard; Serradeil-Le Gal, Claudine; Tonnerre, Bernard; Wagnon, Jean
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055130	A2	20010802	WO 2001-FR226	20010124 <--
WO 2001055130	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2804114	A1	20010727	FR 2000-957	20000125 <--
FR 2804114	B1	20020308		
TW 283672	B	20070711	TW 2001-90101300	20010119 <--
CA 2396814	A1	20010802	CA 2001-2396814	20010124 <--
CA 2396814	C	20070710		
AU 2001035594	A	20010807	AU 2001-35594	20010124 <--
AU 778196	B2	20041118		
BR 2001007807	A	20021022	BR 2001-7807	20010124 <--
EP 1255751	A2	20021113	EP 2001-907685	20010124 <--
EP 1255751	B1	20040616		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002004242	A2	20030528	HU 2002-4242	20010124 <--
HU 2002004242	A3	20040528		
JP 2003523351	T	20030805	JP 2001-560989	20010124 <--
JP 3992498	B2	20071017		
EE 200200409	A	20031215	EE 2002-409	20010124 <--
EE 4779	B1	20070215		
AT 269326	T	20040715	AT 2001-907685	20010124 <--
ES 2222342	T3	20050201	ES 2001-907685	20010124 <--
CN 1193025	C	20050316	CN 2001-804115	20010124 <--
IL 150539	A	20070920	IL 2001-150539	20010124 <--
SK 286976	B6	20090806	SK 2002-1083	20010124 <--
CZ 300917	B6	20090909	CZ 2002-2497	20010124 <--
ZA 2002005224	A	20040309	ZA 2002-5224	20020628 <--
IN 2002MN00890	A	20050304	IN 2002-MN890	20020702 <--
NO 2002003510	A	20020925	NO 2002-3510	20020723 <--
NO 323607	B1	20070618		
BG 106947	A	20030430	BG 2002-106947	20020723 <--
US 20030114683	A1	20030619	US 2002-182048	20020724 <--
US 6730695	B2	20040504		
HR 2002000626	B1	20090430	HR 2002-626	20020724 <--
MX 2002007259	A	20030128	MX 2002-7259	20020725 <--
HK 1050900	A1	20050204	HK 2003-103183	20030505 <--

US 20040209938	A1	20041021	US 2004-835209	20040429	<--
US 7129240	B2	20061031			
US 20070004703	A1	20070104	US 2006-462062	20060803	<--
US 7297692	B2	20071120			

PRIORITY APPLN. INFO.:

FR 2000-957	A	20000125 <--
WO 2001-FR226	W	20010124 <--
US 2002-182048	A3	20020724 <--
US 2004-835209	A3	20040429

OTHER SOURCE(S): MARPAT 135:152717

GI



I

AB Title compds. [(un)substituted I; R = 2,4- or 3,4-dialkoxyphenylsulfonyl; R1 = halo, alkyl, alkoxy, CF3, OCF3; 1 of R2,R7 = OR6 and the other = H; R4 = ZR3; R3 = halo, OH, alkyl, alkoxy, OCF3; R5 = NHEt, NMe2, azetidino, alkoxy; R7 = H, alkyl, alkoxycarbonylalkyl, etc.; Z = (un)substituted 1,2-phenylene] were prepared Thus, 5-chloroindole-2,3-dione was condensed with 2-(MeO)C6H4MgBr and the chlorinated product aminated by (2S,4R)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide (preparation given) to give (+)- and (-)-I [R1 = Cl, R2 = H, R4 = C6H4(OMe)-2, R5 = NMe2, R7 = OH][(+)- and (-)-II; R = H] the latter of which was condensed with 2,4-(MeO)2C6H3SO2Cl to give (-)-II [R = SO2C6H3(OMe)2-2,4]. Data for biol. activity of I were given.

IT 352276-92-7P 352276-93-8P 352276-95-0P
352276-97-2P 352276-99-4P 352277-01-1P
352277-03-3P 352277-05-5P 352277-07-7P
352277-09-9P 352277-11-3P 352277-13-5P
352277-15-7P 352277-17-9P 352277-19-1P
352277-21-5P 352277-23-7P 352277-25-9P
352277-27-1P 352277-29-3P 352277-31-7P
352277-33-9P 352277-35-1P 352277-37-3P
352277-39-5P 352277-41-9P 352277-43-1P
352277-45-3P 352277-47-5P 352277-48-6P
352277-50-0P 352277-52-2P 352277-53-3P
352277-55-5P 352277-57-7P 352277-59-9P
352277-61-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-oxoindolylpyrrolidine-2-carboxamides and analogs as vasopressin V1a and V1b receptor ligands)

RN 352276-92-7 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-93-8 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-95-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-97-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352276-99-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-01-1 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-03-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-05-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-07-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-09-9 HCAPLUS
CN 2H-Indol-2-one, 3-[(2S,4R)-2-(1-azetidinylcarbonyl)-4-hydroxy-1-pyrrolidinyl]-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-11-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-5-(trifluoromethoxy)-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-13-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-15-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5,6-dimethyl-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-17-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-19-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-21-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[6-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-5-methyl-2-oxo-1H-indol-3-yl]-4-methoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-23-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-ethoxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-25-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-27-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-29-3 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-31-7 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-hydroxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-33-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-35-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-[2-(trifluoromethoxy)phenyl]-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-37-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,3-difluorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-39-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-3-(2,4-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-41-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[3-(1,3-benzodioxol-4-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-43-1 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5,6-dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-45-3 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-47-5 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 352277-48-6 HCAPLUS
CN Acetic acid, 2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 352277-47-5
CMF C32 H34 Cl N3 O10 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 352277-50-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-[2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-2-oxoethoxy]-N,N-dimethyl-, (2S,4R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 352277-52-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-oxo-2-(1-piperazinyl)ethoxy]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-53-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-oxo-2-(1-piperazinyl)ethoxy]-, (2S,4R)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 352277-52-2
CMF C36 H42 Cl N5 O9 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 352277-55-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-N,N-dimethyl-4-[2-(4-morpholinyl)-2-oxoethoxy]-, (2S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-57-7 HCAPLUS
CN 4-Morpholinepropanoic acid, (3R,5S)-1-[(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-59-9 HCAPLUS
CN 4-Morpholinepropanoic acid, (3R,5S)-1-[(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 352277-61-3 HCAPLUS
CN L-Proline, 1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-methoxy-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 352278-78-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-oxoindolylpyrrolidine-2-carboxamides and analogs as vasopressin V1a and V1b receptor ligands)

RN 352278-78-5 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[(3R,5S)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]oxy]acetyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (25 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:31498 HCAPLUS Full-text
DOCUMENT NUMBER: 134:86237
TITLE: Preparation of thiazolidinyl substituted indoles for the treatment of cancer
INVENTOR(S): Chin, Allison C.; Tolman, Richard L.; Nguyen, Mark Q.; Holcomb, Ryan
PATENT ASSIGNEE(S): Geron Corporation, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001002394	A1	20010111	WO 2000-US18112	20000630	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1109808	A1	20010627	EP 2000-946946	20000630	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 6372742	B1	20020416	US 2000-608861	20000630	<--
US 20020115700	A1	20020822	US 2002-77738	20020213	<--
PRIORITY APPLN. INFO.:			US 1999-142173P	P 19990701	<--
			US 2000-608861	A1 20000630	<--
			WO 2000-US18112	W 20000630	<--

OTHER SOURCE(S): MARPAT 134:86237
GI



I



II

AB The title compds. [I; X1 = O, S, CH2, NR5 (wherein R5 = H, alkyl, aryl); L1 = a single or double bond, CH2, CH; R1 = H, OR5, SR5, etc.; R2, R3 = H, OH, halo, etc.; L2 = a bond, a linking group having 1-3 atoms selected from (un)substituted C, N, O, S; R4 = H, alkyl, alkaryl, etc.], useful in inhibiting telomerase activity and treatment of telomerase mediated conditions or diseases such as cancer, were prepared E.g., a 2-step synthesis of the indole II was given. The exemplified compds. I were tested for telomerase inhibition and showed IC50 of < 100 μM.

IT 318294-74-5P 318294-77-8P 318294-32-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinyl substituted indoles for the treatment of cancer)

RN 318294-74-5 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[5-chloro-1,2-dihydro-1-[(4-methylphenyl)sulfonyl]-2-oxo-3H-indol-3-ylidene]- (CA INDEX NAME)



RN 318294-77-8 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[5-chloro-1,2-dihydro-1-[(4-nitrophenyl)sulfonyl]-2-oxo-3H-indol-3-ylidene]- (CA INDEX NAME)



RN 318294-82-5 HCAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[3-(2,4-dioxo-5-thiazolidinylidene)-2,3-dihydro-2-oxo-1H-indol-1-yl]sulfonyl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:393896 HCAPLUS Full-text
DOCUMENT NUMBER: 125:58502
ORIGINAL REFERENCE NO.: 125:11249a,11252a
TITLE: Preparation of thiazolidinylideneindolinone derivatives as cell migration inhibitors
INVENTOR(S): Niigata, Kunihiro; Furuichi, Kyoshi; Masuoka, Kota; Hirose, Toshihiro; Sasamata, Yoshiho; Kon, Akinari; Jooji, Nikorasu Panayotoo; Maikeru, Dereku Uootaafuiirudo
PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan; Ruudobitsuhi Inst Fuoa Kyansaa
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 08092248 A 19960409 JP 1994-229872 19940926 <--
PRIORITY APPLN. INFO.: JP 1994-229872 19940926 <--
OTHER SOURCE(S): MARPAT 125:58502
GI



I

AB The title compds., e. g. I [B = S, etc.; A = CO, etc.; R = halo; n = 0 to 5], useful as PDGF-induced cell migration inhibitors (no data) for the treatment of inflammation, atherosclerosis, etc., are prepared I [B = S; A = CO; n = 2; R = 3-Cl and 4-Cl] was prepd . in a 2-step process starting with isatin and 3,4-dichlorobenzoyl chloride.

IT 178241-22-0P 178241-23-1P 178241-24-2P
178241-25-3P 178241-30-0P 178241-31-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinylideneindolinone derivs. as cell migration inhibitors)

RN 178241-22-0 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-oxo-2-thioxo-5-thiazolidinylidene)-1-[(2,4,5-trichlorophenyl)sulfonyl]- (CA INDEX NAME)



RN 178241-23-1 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[1,2-dihydro-2-oxo-1-[(2,4,5-trichlorophenyl)sulfonyl]-3H-indol-3-ylidene]- (CA INDEX NAME)



RN 178241-24-2 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[1,2-dihydro-2-oxo-1-(phenylsulfonyl)-3H-indol-3-ylidene]- (CA INDEX NAME)



RN 178241-25-3 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-(4-oxo-2-thioxo-5-thiazolidinylidene)-1-(phenylsulfonyl)- (CA INDEX NAME)



RN 178241-30-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[1-[(2,5-dichlorophenyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]- (CA INDEX NAME)



RN 178241-31-1 HCAPLUS
CN 2H-Indol-2-one, 1-[(2,5-dichlorophenyl)sulfonyl]-1,3-dihydro-3-(4-oxo-2-thioxo-5-thiazolidinylidene)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L9 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:858609 HCAPLUS Full-text
DOCUMENT NUMBER: 123:256516
ORIGINAL REFERENCE NO.: 123:45875a,45878a
TITLE: Indol-2-one derivatives substituted in the 3-position by a nitrogenous group, their preparation, and pharmaceutical compositions containing them as vasopressin and/or oxytocin receptor ligands.
INVENTOR(S): Wagnon, Jean; Tonnerre, Bernard; Di Malta, Alain; Roux, Richard; Amiel, Marie-Sophie; Serradeil-Legal, Claudine
PATENT ASSIGNEE(S): Sanofi, Fr.
SOURCE: Fr. Demande, 70 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2714378	A1	19950630	FR 1993-15638	19931224 <--
FR 2714378	B1	19960315		
WO 9518105	A1	19950706	WO 1994-FR1528	19941223 <--
W: JP, LT, SI, US				

```
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     EP 687251          A1    19951220    EP 1995-905164         19941223 <--
     EP 687251          B1    20020227
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     JP 08507092        T     19960730    JP 1994-517812         19941223 <--
     JP 3263081         B2    20020304    JP 1995-517812         19941223 <--
     AT 213727          T     20020315    AT 1995-905164         19941223 <--
     ES 2173172         T3    20021016    ES 1995-905164         19941223 <--
     US 5594023         A     19970114    US 1995-500924         19950731 <--
     US 5773612         A     19980630    US 1996-640080         19960430 <--
PRIORITY APPLN. INFO.:                    FR 1993-15638       A  19931224 <--
                                          WO 1994-FR1528      W  19941223 <--
                                          US 1995-500924      A3 19950731 <--
OTHER SOURCE(S):          CASREACT 123:256516; MARPAT 123:256516
GI
```



I



II

AB Title compds. I [R1, R2 = H, halo, alkyl, alkoxy, CF3; R3 = alkyl, cycloalkyl, (di)alkylcyclohexyl, (un)substituted Ph; R4 = N3, alkylsulfonamido, (un)substituted phenylsulfonamido, dimethylaminosulfonamido, (un)substituted NH2, heterocyclyl; R5 = H, R6; R6 = halo, alkyl, CF3, cyano, (di)(alkyl)aminomethyl, NO2, (un)substituted amino, carboxy, carbamoyl, acyl, etc.; X = SO2, CH2; m = 1, and sometimes 2-4] and salts are claimed, and approx. 100 examples are given. The compds. have affinity for vasopressin and/or oxytocin receptors, and are useful for treating disorders of the central and peripheral nervous, cardiovascular, renal, and gastric systems, as well as sexual disorders. For example, bromination of 5-chloro-1,3-dihydro-3-phenylindol-2-one with Br2 in CCl4 gave the 3-bromo derivative, which reaced with anhydrous NH3 in Et2O to give the 3-amino derivative Treatment of this with NaH in DMF and then with 2,4-(MeO)2C6H3SO2Cl yielded title compound II. In a test for inhibition of binding of [3H]-arginine-vasopressin to bovine renal V2 receptors, I had IC50 down to 10-9 M.

IT 169039-90-1P 169040-06-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indolone derivs. as vasopressin and/or oxytocin receptor ligands)

RN 169039-90-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 169040-06-6 HCAPLUS
CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(1-piperidinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:72349 HCAPLUS Full-text
DOCUMENT NUMBER: 86:72349
ORIGINAL REFERENCE NO.: 86:11455a,11458a
TITLE: Behavior of N-(substituted thio)phthalimides, N-(substituted thio)succinimides, and N-(substituted thio)isatins toward some nucleophiles
AUTHOR(S): Furukawa, Mitsuru; Suda, Tchiaki; Hayashi, Seigoro
CORPORATE SOURCE: Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1976), 24(8), 1708-13
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI


I


II


III

AB New compds. of N-(substituted thio)isatins I (R = Ph, m-MeC6H4, o-O2NC6H4, p-ClC6H4, PhCH2) were synthesized and reactions with several nucleophiles were examined in comparison with the reaction using N-(substituted thio)phthalimides II and N-(substituted thio)succinimides III (R = Ph, p-MeC6H4, o-O2NC6H4, PhCH2). All of I, II, and III reacted with organometallic compds., cyanide ion, and trichloromethyl carbanion to give sulfides, thiocyanates, and trichloromethyl sulfides resp. The reaction of I with amines gave 3-amino-1-(substituted thio)-3-hydroxy-2-oxoindoles.

IT 61639-73-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61639-73-4 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-hydroxy-3-(4-morpholinyl)-1-[(2-nitrophenyl)thio]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

```
=> d his nofile

     FILE 'REGISTRY' ENTERED AT 14:22:59 ON 13 NOV 2009
L1             STR
L3          2698 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 14:31:37 ON 13 NOV 2009
L5            66 SEA ABB=ON  PLU=ON  L3
L6            16 SEA ABB=ON  PLU=ON  L5 AND (AY=<2003 OR PY=<2003 OR PRY=<2003
                 OR PD=< OCTOBER 30, 2003)
L7            12 SEA ABB=ON  PLU=ON  L5(L)(?DRUG? OR ?PHARMA? OR ?MEDIC? OR
                 ?THERAP?)
L8             4 SEA ABB=ON  PLU=ON  L6 AND L7
                 D STAT QUE L8
                 D IBIB ABS HITSTR L8 1-4
L9            12 SEA ABB=ON  PLU=ON  L6 NOT L8
                 D STAT QUE L9
                 D IBIB ABS HITSTR L9 1-12

=>
```